BACKGROUND: Melanoma-associated antigen-A4 (MAGE-A4) is one of the candidates for a target of immunotherapy and is expressed in non-small cell lung cancer (NSCLC). However, tumors sometimes lose human leukocyte antigen (HLA) class I expression, and tumor-specific T cells cannot eliminate the tumor with loss of HLA. However, the relationship between MAGE-A4 expression and HLA loss has remained unclear. METHODS: Among 363 NSCLC patients who consecutively underwent curative surgery, 187 cases whose material could be analyzed were reviewed. The expression of HLA class I molecules was assessed by immunohistochemical staining. The expression of MAGE-A4 was analyzed by RT-PCR. RESULTS: Seventy-seven tumors expressed HLA normally; however, 110 tumors lost HLA. The proportion of patients with a smoking habit and expressing the MAGE-A4 gene in patients with HLA loss was higher than those with HLA expression (p = 0.04 and 0.028, respectively). Five-year overall survival (OS) rate in the patients expressing MAGE-A4 but with loss of HLA was 52.4 %, and OS was significantly poorer than their counterparts (74.0 %, p = 0.036). Multivariate analysis indicated that advanced stage or history of smoking and HLA loss was an independently poor prognostic predictor of OS in NSCLC (p < 0.01 and p = 0.04, respectively). CONCLUSION: HLA class I loss in NSCLC was related to smoking history and MAGE-A4 expression of tumors. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in NSCLC.
BACKGROUND:Melanoma-associated antigen-A4 (MAGE-A4) is one of the candidates for a target of immunotherapy and is expressed in non-small cell lung cancer (NSCLC). However, tumors sometimes lose human leukocyte antigen (HLA) class I expression, and tumor-specific T cells cannot eliminate the tumor with loss of HLA. However, the relationship between MAGE-A4 expression and HLA loss has remained unclear. METHODS: Among 363 NSCLCpatients who consecutively underwent curative surgery, 187 cases whose material could be analyzed were reviewed. The expression of HLA class I molecules was assessed by immunohistochemical staining. The expression of MAGE-A4 was analyzed by RT-PCR. RESULTS: Seventy-seven tumors expressed HLA normally; however, 110 tumors lost HLA. The proportion of patients with a smoking habit and expressing the MAGE-A4 gene in patients with HLA loss was higher than those with HLA expression (p = 0.04 and 0.028, respectively). Five-year overall survival (OS) rate in the patients expressing MAGE-A4 but with loss of HLA was 52.4 %, and OS was significantly poorer than their counterparts (74.0 %, p = 0.036). Multivariate analysis indicated that advanced stage or history of smoking and HLA loss was an independently poor prognostic predictor of OS in NSCLC (p < 0.01 and p = 0.04, respectively). CONCLUSION: HLA class I loss in NSCLC was related to smoking history and MAGE-A4 expression of tumors. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in NSCLC.
Authors: F Liu; J K Killian; M Yang; R L Walker; J A Hong; M Zhang; S Davis; Y Zhang; M Hussain; S Xi; M Rao; P A Meltzer; D S Schrump Journal: Oncogene Date: 2010-05-03 Impact factor: 9.867
Authors: Yen-Tsung Huang; Xihong Lin; Yan Liu; Lucian R Chirieac; Ray McGovern; John Wain; Rebecca Heist; Vidar Skaug; Shanbeh Zienolddiny; Aage Haugen; Li Su; Edward A Fox; Kwok-Kin Wong; David C Christiani Journal: Proc Natl Acad Sci U S A Date: 2011-09-12 Impact factor: 11.205
Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon Journal: Science Date: 1991-12-13 Impact factor: 47.728
Authors: L E Hays; D M Zodrow; J E Yates; M E Deffebach; D B Jacoby; S B Olson; J F Pankow; G C Bagby Journal: Br J Cancer Date: 2008-05-13 Impact factor: 7.640
Authors: P Iniesta; R González-Quevedo; A Morán; C García-Aranda; C de Juan; A Sánchez-Pernaute; A Torres; E Díaz-Rubio; J L Balibrea; M Benito Journal: Br J Cancer Date: 2004-05-17 Impact factor: 7.640
Authors: Mehrdad Talebian Yazdi; Sander van Riet; Annemarie van Schadewijk; Marta Fiocco; Thorbald van Hall; Christian Taube; Pieter S Hiemstra; Sjoerd H van der Burg Journal: Oncotarget Date: 2016-01-19